Coenzyme Q-10 and Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension Clinical Trial

Official title:

Coenzyme Q-10 in the Treatment of Pulmonary Arterial Hypertension

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01148836
• Other study ID #: 08-497
• Status: Completed
• Phase: N/A
• First received: March 19, 2010
• Last updated: March 19, 2015
• Start date: January 2010
• Est. completion date: January 2014

Study information

• Verified date: March 2015
• Source: The Cleveland Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of Coenzyme Q-10, an antioxidant, in the treatment of pulmonary hypertension.

Description:

Abnormalities in the blood vessels in the lung are the hallmark of pulmonary hypertension. Links between increased free radical production, mitochondrial dysfunction and pulmonary hypertension have been studied but are poorly understood. The mitochondria of cells is the location where cellular energy is created and free radicals are atoms or groups of atoms with an odd (unpaired) number of electrons and can be formed when oxygen interacts with certain molecules. Once formed these reactive radicals can start a chain reaction, like dominoes. Their chief danger comes from the damage they can do when they react with important cellular components. Cells may function poorly or die if this occurs. The body produces free radicals in the normal course of energy production and in pulmonary hypertension, free radical production is found to be increased. To prevent free radical damage the body has a defense system of antioxidants. Coenzyme Q-10 is an antioxidant and it helps to protect cells from damage caused by the body's own free radicals. By providing oral supplementation of coenzyme Q-10, free radical levels will be decreased and cellular functioning in the pulmonary blood vessels may improve and even return to near normal functioning.

The purpose of this study is to evaluate the effects of coenzyme Q-10, an antioxidant, in the treatment of pulmonary hypertension. We will assess coenzyme Q-10 supplementation in the treatment of pulmonary hypertension by clinical measurements and blood levels of certain cellular components. We would like to assess the effects of coenzyme Q-10 on the pulmonary vessels by measuring the lung diffusing capacity (a breathing test) and exhaled Nitric Oxide (NO) (a substance in the body that relaxes or dilates blood vessels). We will also measure endothelial progenitor cells (cells from the bone marrow) from a blood sample; these cells are markers of measure of blood vessel formation and repair. We will also measure the activity of superoxide dismutase (a protein in cells that executes the breakdown of a free radical into oxygen and hydrogen peroxide) in the blood. In addition, we will measure levels of coenzyme Q-10 in the blood. Other markers of disease response to therapy will be done including physical exam, BNP level (a blood marker that correlates with heart function), 6-minute walk and echocardiography (ultrasound of the heart). A total of 60ml (5 tablespoons) of blood will be drawn at each visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: January 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Males and Females age equal to or greater than 18 not to exceed 65.

• Patients with PAH Class 1 (Venice 2003)

• PAH medications must not have changed for the last two months.

• Women of child-bearing age must use a double-barrier local contraception until completion of study.

• Subjects must demonstrate understanding of study and sign informed consent and have a reliable method of communication for contact and the ability to comply with the study requirements.

Exclusion Criteria:

• Participation in any other studies at the time of enrollment

• History of any significant illness within four weeks of starting Coenzyme Q-10

• Hepatic insufficiency (transaminase levels >4 fold the upper limit of normal or bilirubin >2 fold the upper limit of normal).

• Renal insufficiency (creatinine >2)

• Pregnancy,breast-feeding or lack of safe contraception.

• Acute heart failure

• Known allergy to the study drug or drugs similar to the study drug

• History of drug or alcohol abuse within last 12 months

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertension
• Pulmonary Arterial Hypertension

Intervention

Dietary Supplement:
• Coenzyme Q-10 in Pulmonary Hypertension subjects
Take 100mg Co-Q for three times daily
• Coenzyme Q-10 in Normal Control subjects
Take 100mg Co-Q for three times daily

Locations

Country	Name	City	State
United States	Cleveland Clinic	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Left Ventricular End Diastolic Volume	Amount of blood in ventricle at end of diastole	before and after three months of CoQ	No
Primary	Right Ventricular Outflow	Velocity time interval	before and after three months of CoQ	No
Primary	Right Ventricle Myocardial Performance	Tei Index=(IRT+ICT)/ET, where IRT is isovolumic	before and after three months of CoQ	No
Primary	Tricuspid Regurgitation Grade	Tricuspid Regurgitation Grade ranges from 1 (normal) to 4 (severe regurgitation)	before and after three months of CoQ	No
Primary	Right Atrial Pressure		before and after three months of CoQ	No
Secondary	Red Blood Cells		before and after three months of CoQ	No
Secondary	Hemoglobin		before and after three months of CoQ	No
Secondary	Hematocrit		before and after three months of CoQ	No
Secondary	Mean Corpuscular Hemoglobin		before and after three months of CoQ	No
Secondary	Red Blood Cell Distribution Width		before and after three months of CoQ	No